Pasireotide
Also known as: signifor, SOM230
Multi-receptor somatostatin analogue studied for Cushing's disease and acromegaly.
Quick Reference
Pasireotide - Research Images
PSO vial render · Scientific images from Wikipedia · Tap to enlarge
Overview
Pharmaceutical drug
Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.
Mechanism of Action
Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.
What Researchers Are Saying
Community Reports - Not Medical Advice
The following is aggregated from public forums, Reddit, and research communities. These are anecdotal reports from researchers only - not verified clinical data and not a recommendation of any kind.
Pasireotide (also known as signifor, SOM230) is studied within the peptide research community. Multi-receptor somatostatin analogue studied for Cushing's disease and acromegaly.
Last updated October 28, 2026
Research status: active. Pasireotide appears across peptide research forums and academic literature. Researchers note this compound falls in the other category.
Last updated October 28, 2026
What Do You Think of This Peptide?
Share your opinion or research experience with Pasireotide. Comments are reviewed before appearing.